A Feasibility Trial of Eye Movement Desensitization and Reprocessing Therapy- Integrative Treatme… (NCT07027930) | Clinical Trial Compass
RecruitingNot Applicable
A Feasibility Trial of Eye Movement Desensitization and Reprocessing Therapy- Integrative Treatment Group Protocol for Ongoing Traumatic Stress In Road Traffic Accident Survivors for Reduction of Post-traumatic Stress Symptoms
Pakistan35 participantsStarted 2025-05-01
Plain-language summary
Road traffic accidents (RTAs) are a significant public health concern globally, accounting for a substantial proportion of morbidity and mortality. This study evaluates the feasibility and acceptability of the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol for Ongoing Traumatic Stress (EMDR-IGTP-OTS) in the reduction of posttraumatic stress symptoms, depression, and anxiety, while improving the quality of life in individuals who have experienced traffic accidents. Using a randomized control design, participants aged 18-45 will be assessed at three-time points: pre-treatment, post-treatment, and one-month follow-up. The study employs the DASS-21, UIES-R, and WHOQOL-BREF as evaluation measures. Findings aim to expand evidence on trauma-focused interventions and explore their applicability in culturally diverse, resource-constrained settings.
Who can participate
Age range
18 Years – 45 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged between 18 and 45 years.
* Experienced a traffic accident 3 months to 10 years prior
* Willing to participate and able to understand the intervention components.
Exclusion Criteria:
* Participants will be excluded from the study if they meet any of the following criteria:
* Diagnosed with conditions such as schizophrenia or bipolar disorder, which require specialized treatment beyond the scope of this study.
* History of severe head injuries resulting in neurological or cognitive deficits.
* Participants who have experienced a traffic accident less than 3 months ago, as immediate post-traumatic responses may not have stabilized
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The Urdu Impact of Event Scale-Revised
Timeframe: From Enrollment to end of study after 4 weeks